Vera Therapeutics, Inc. (VERA) Stock Price & Analysis
Vera Therapeutics, Inc. (VERA) rose 0.19% to USD 31.81 as of June 10, 2026 at 03:07 UTC, according to Nexqual real-time market data.
VERA last closed at USD 31.75; the session ranged USD 30.82–32.9 on volume of 887,561 shares. Market capitalization is $2.28B, with a 52-week range of USD 19.07–56.05 (NGM). Source: Nexqual, June 10, 2026 at 03:07 UTC.
Key Statistics (as of June 10, 2026 at 03:07 UTC)
| Price | USD 31.81 |
|---|---|
| Change | ▲ 0.19% (up) |
| Previous Close | USD 31.75 |
| Open | USD 32.44 |
| Day Range | USD 30.82 – 32.9 |
| 52-Week Range | USD 19.07 – 56.05 |
| Volume | 887,561 shares |
| Market Cap | $2.28B |
| Exchange | NGM |
Technical Analysis (VERA)
Nexqual's technical model rates VERA "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:07 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.32 (neutral) |
| vs SMA50 | Below (USD 37.32) |
| MACD | -1.49 (negative) |
Analyst Ratings (VERA)
Wall Street analysts rate VERA "Strong Buy" based on 14 analysts, with a mean price target of USD 78 (range USD 35–110), per Nexqual as of June 10, 2026 at 03:07 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 78 |
| High Target | USD 110 |
| Low Target | USD 35 |
| Buy / Hold / Sell | 13 / 1 / 0 |
Earnings (VERA)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD -1.71 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.69 vs est -1.37 ▼ miss |
| 2025-12-31 | USD -1.39 vs est -1.27 ▼ miss |
| 2025-09-30 | USD -1.26 vs est -1.13 ▼ miss |
| 2025-06-30 | USD -1.2 vs est -0.62 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
Financials & Fundamentals (VERA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -71.32% |
| Debt / Equity | 15.39 |
| Current Ratio | 13.64 |
| Total Cash | $596.76M |
| Total Debt | $76.89M |
| Free Cash Flow | $-179.42M |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
Financial Health Score (VERA)
Nexqual rates Vera Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:07 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $597M cash vs $77M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$293M |
| Efficiency | Critical — ROE -71%, ROA -38.9% |
Ownership (VERA)
| Insider Ownership | +0.87% |
|---|---|
| Institutional Ownership | +110.60% |
| Shares Outstanding | 71.78M |
| Float | 52.06M |
| Short % of Float | +17.19% |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
Leadership (VERA)
Vera Therapeutics, Inc. is led by Marshall W. Fordyce (age 50), Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 03:07 UTC.
| Founder, President, CEO & Director | Marshall W. Fordyce (age 50) |
|---|---|
| Chief Financial Officer | Sean P. Grant (age 40) |
| Vice President of Corporate Communications | Debra Charlesworth |
| Vice President of Marketing | Emma Haywood |
Major Backers & Investors (VERA)
Notable institutional backers of Vera Therapeutics, Inc. include Avoro Capital Advisors LLC, Price (T.Rowe) Associates Inc, Deep Track Capital, Lp, according to Nexqual as of June 10, 2026 at 03:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Avoro Capital Advisors LLC | 8.2% |
| Price (T.Rowe) Associates Inc | 6.37% |
| Deep Track Capital, Lp | 5.72% |
| Deerfield Management Company, L.P | 5.19% |
| Kynam Capital Management, LP | 4.73% |
| T. Rowe Price | 4.24% |
| Sofinnova Investments, Inc. | 3.89% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.11% |
| State Street | 7.67% |
| Vanguard Group | 7.39% |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
From Vera Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.
- The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
- It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| JANX | Janux Therapeutics, Inc. | USD 13.62 | ▲ 1.95% |
| EWTX | Edgewise Therapeutics, Inc. | USD 34.06 | ▼ 4.3% |
| KYMR | Kymera Therapeutics, Inc. | USD 76.91 | ▲ 3.75% |
| NUVL | Nuvalent, Inc. | USD 123.25 | ▲ 35.51% |
| TVTX | Travere Therapeutics, Inc. | USD 48.57 | ▲ 6.02% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:07 UTC. This page is informational and not investment advice.